Neurocrine Biosciences, Inc.
NASDAQ:NBIXBiotechnology
-$0.71 today
- Market cap
- $16.48B
- Beta
- 0.40
- P/E (TTM)
- 23.8
- EPS (TTM)
- $6.65
Volume 1.60M
Average 1.18M
NBIX Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Neurocrine Biosciences, Inc.NASDAQ: NBIX
Accounts Receivables · Q3 FY2026 · quarter ended Sep 2026
Accounts receivables declines year over year
Q3 FY2026 accounts receivables of $70.2M (cash outflow) fell 46.9% year over year, behind the -20.0% change in trailing-twelve-month accounts receivables. Sequentially, it fell 16.7% from the prior quarter. Over 3 fiscal years it compounded at +9.1% a year.
Context
- Accounts receivables amounted to 7.4% of revenue in FY2025, up 5.7 pp from a year earlier.
- Accounts receivables grew in size in 1 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -46.9% toward the trailing-twelve-month pace of -20.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- (210.5M) USD
- Year-over-year change
- -428.9%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (210.5M) | -428.9% |
| FY2024 | 2024-12-31 | (39.8M) | +55.4% |
| FY2023 | 2023-12-31 | (89.3M) | +44.9% |
| FY2022 | 2022-12-31 | (162.2M) | -471.1% |
| FY2021 | 2021-12-31 | (28.4M) | — |
Accounts Receivables vs competitors
How NBIX compares with its peers on the latest reported figures
- NBIX's LTM Sep 2026 accounts receivables of $197.5M is the largest of the 10 companies compared; the peer median is $12.33M.
- Its year-over-year change of -20.0% is the 5th highest of 6, against a peer median of +0.2%.
- Accounts receivables amounts to 5.3% of revenue for NBIX, versus a peer median of 4.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $197.5M | -20.0% | +9.1% | 5.3% | |
| LTM Jun 2026 | $78.63M | +0.2% | +29.8% | 10.1% | |
| LTM Jun 2026 | $47.41M | -506.5% | +10.9% | 5.7% | |
| LTM Jun 2026 | $46.65M | +402.0% | — | 4.1% | |
| LTM Sep 2026 | $37.81M | -4.5% | +5.6% | 0.8% | |
| LTM Mar 2026 | $12.33M | +56.3% | +89.9% | 5.7% | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $58K | — | — | 0.3% |
| LTM Jun 2026 | $0 | — | — | — | |
| LTM Mar 2026 | $0 | — | — | — | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $0 | — | — | — |
| Peer median (excluding NBIX) | $12.33M | +0.2% | +20.3% | 4.9% | |
Competitors are the stored peer set for NBIX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 89.6M | 154.5M | 249.7M | 341.3M | 478.6M |
| Depreciation & Amortization | 10.9M | 15.6M | 21.3M | 27.1M | 30.1M |
| Deferred Income Tax | 4.3M | 19.1M | (56.7M) | (123.1M) | 165.4M |
| Stock-Based Compensation | 134.2M | 173.1M | 194.3M | 195.5M | 217.9M |
| Change in Working Capital | 16.7M | (67.4M) | 28.2M | (19.2M) | (128.8M) |
| Accounts Receivables | (28.4M) | (162.2M) | (89.3M) | (39.8M) | (210.5M) |
| Inventory | (2.5M) | (2.6M) | 5.4M | (19.1M) | (15.3M) |
| Accounts Payables | 0 | 0 | 0 | 0 | 0 |
| Other Working Capital | 47.6M | 97.4M | 112.1M | 39.7M | 97M |
| Other Non-Cash Items | 800K | 44.5M | (46.9M) | 173.8M | 19.5M |
| Operating Cash Flow | 256.5M | 339.4M | 389.9M | 595.4M | 782.7M |
| Capital Expenditures | (23.4M) | (16.5M) | (28.3M) | (38.2M) | (34M) |
| Acquisitions (Net) | 0 | (42.7M) | 0 | 0 | 0 |
| Purchases of Investments | (804.7M) | (628.9M) | (1.41B) | (1.06B) | (1.32B) |
| Sales of Investments | 697.9M | 511M | 972.4M | 967.5M | 1.09B |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (130.2M) | (177.1M) | (467.1M) | (126.8M) | (264.4M) |
| Debt Repayment | (100K) | (279M) | 0 | (308.8M) | 0 |
| Common Stock Issued | 27.5M | 44.7M | 65.3M | 122.1M | 129.4M |
| Common Stock Repurchased | 0 | 0 | 0 | (300M) | (167.7M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 27.4M | (234.3M) | 65.3M | (486.7M) | (38.3M) |
| Effect of Forex Changes | 0 | (1.3M) | 300K | 0 | 0 |
| Net Change in Cash | 153.7M | (73.3M) | (11.6M) | (18.1M) | 480M |
| Free Cash Flow | 233.1M | 322.9M | 361.6M | 557.2M | 748.7M |
Neurocrine Biosciences, Inc.
NASDAQ:NBIX
Intrinsic Alpha fair value
Locked
Current Price
$162.86
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.